SWISS DRUG DELIVERY FIRM LICENSES FAST-ACTING DICLOFENAC PRODUCTS TO U.S. BASED PROETHIC PHARMACEUTICALS

Applied Pharma Research (APR), a Swiss-based R&D firm that specializes in enhancing drug delivery, and ProEthic Pharmaceuticals Inc., announced today that APR has granted an exclusive license to ProEthic to develop and market two fast-acting formulations of diclofenac potassium in the U.S. and Canada. Diclofenac potassium, commonly referred to as an "NSAID" (non-steroidal anti-inflammatory drug), was originally marketed by Novartis in the 1990's for the treatment of rheumatoid and osteoarthritis, dysmenorrhea and mild to moderate pain.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1053094XSL_NEWSML_TO_NEWSML_WEB.xml)